Quantcast

Latest Basiliximab Stories

2011-06-15 16:13:00

SILVER SPRING, Md., June 15, 2011 /PRNewswire-USNewswire/ --The U.S. Food and Drug Administration today approved Nulojix (belatacept) to prevent acute rejection in adult patients who have had a kidney transplant. The drug is approved for use with other immunosuppressants (medications that suppress the immune system) -- specifically basiliximab, mycophenolate mofetil, and corticosteroids. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Nulojix is a type of drug called a...

2011-05-19 13:53:41

In the first head-to-head comparison of the three most common drugs used at the time of a kidney transplant to prevent organ rejection, researchers found that the least expensive drug "“ at one-half to one-fifth the price "“ is as safe and effective as the other two, according to a paper published by University of Alabama at Birmingham researchers in the May 19, 2011, issue of the New England Journal of Medicine. Based at UAB, researchers in the INTAC trial spent three years...

2011-04-15 14:00:18

Kidney transplant recipients who develop antibodies in response to receiving new organs can develop accelerated arteriosclerosis, or narrowing of the arteries that supply blood to the kidney, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results indicate that arteriosclerosis resulting from such donor-specific antibodies may play an important role in organ rejection following transplantation. Antibody-mediated transplant...

2011-02-11 14:29:00

Test monitors level of a drug that helps prevent kidney rejection SILVER SPRING, Md., Feb. 11, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today announced that it has cleared a test to help manage potential organ rejection in kidney transplant patients. The test, called QMS Everolimus Immunoassay, monitors the blood level of everolimus, a drug that helps prevent rejection in kidney transplants. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)...

2008-07-09 09:00:12

SOUTH SAN FRANCISCO, July 9 /PRNewswire/ -- Cerimon Pharmaceuticals, Inc., announced today it has initiated a Phase II proof-of-concept study of Simulect(R) (basiliximab) for the treatment of noninfectious uveitis, a chronic and potentially sight-threatening inflammation of the eye. The randomized, double-masked, placebo-controlled study will evaluate the safety and efficacy of Simulect as maintenance therapy in 56 patients. During the study, patients will undergo tapering of concomitant...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related